# HHS Updates Testosterone Therapy Labels Over Prostate Cancer Risk
The Department of Health and Human Services is requiring manufacturers to update warning labels on testosterone therapies to clarify risks for men with prostate cancer and those with hypogonadism, the condition of abnormally low testosterone.
The label revisions address confusion about which patients should avoid testosterone treatment. Men with a history of prostate cancer face elevated risk when using testosterone therapy, as the hormone can stimulate prostate cancer growth. The updated labels will make this contraindication clearer for prescribers and patients.
Hypogonadism affects men whose bodies produce insufficient testosterone naturally. These patients often benefit from replacement therapy, but doctors must screen carefully for undiagnosed prostate cancer before starting treatment. The revised labels will emphasize this screening requirement.
This action follows years of debate among endocrinologists and urologists about testosterone therapy safety. The FDA has previously warned about cardiovascular risks associated with testosterone use, particularly in older men. These new label updates focus specifically on prostate-related concerns.
Parents and partners of men considering testosterone therapy should understand the distinction between treatment for genuine hypogonadism and off-label use for age-related decline. Men over 40 often experience natural testosterone decreases, but this differs from clinical hypogonadism. Doctors diagnose hypogonadism through blood tests showing testosterone levels below 300 nanograms per deciliter.
Before starting any testosterone therapy, men need baseline prostate screening through PSA blood tests and digital rectal exams. This conversation matters for families because men sometimes pursue testosterone treatment without full medical evaluation, especially when seeking energy boosts or muscle gains.
The label updates represent the HHS response to real safety concerns. Testosterone therapy remains appropriate for men with documented hypogonadism and no prostate cancer history, but treatment requires careful medical oversight